Physician profile
David Abbasi
NPI 1790947398
$10,963.49
in general payments reported to CMS, 2019-2025
14 companies · $4,988 in 2025
The $4,988 reported for 2025 was more than what 81% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,905 · 2020: $46.95 · 2021: $1,389 · 2022: $1,612 · 2023: $22.46 · 2025: $4,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,800 · Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,800.00 |
| Food and Beverage | $210.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $5,092.24 | 2021-2025 | Bone Anchors With Arthroscopic Delivery System, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Arthrex, INC. | $1,803.36 | 2019-2022 | |
| Arthrosurface Incorporated | $1,520.24 | 2019 | |
| Southern Edge Orthopaedics, INC. | $1,343.76 | 2021-2022 | |
| Medinc of Texas | $478.54 | 2019 | |
| Depuy Synthes Sales INC. | $188.25 | 2025 | Inhance |
| Zimmer Biomet Holdings, INC. | $167.01 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $133.14 | 2021-2022 | |
| Embody, INC. | $74.72 | 2022 | |
| Djo, LLC | $48.54 | 2022 | |
| Wright Medical Technology, INC. | $46.95 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $29.73 | 2021-2022 | |
| Abbott Laboratories | $22.46 | 2023 | Proclaim |
| Bioventus LLC | $14.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.